• Achieve Life Sciences announced positive results from its year-long ORCA-OL cytisinicline trial, presented at the CHEST 2026 Annual Meeting.
• Quit rates rose during treatment among adults still smoking or vaping following a previous medically supported quit attempt.
• The open-label findings suggest extended treatment could help sustain abstinence; independent safety monitoring identified no new safety signals.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Achieve Life Sciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610210830PRIMZONEFULLFEED9850088) on October 21, 2026, and is solely responsible for the information contained therein.